US private equity firm Veritas Capital has agreed to acquire Bodycote, the UK-based heat-treatment specialist, in a deal valued at £1.85 billion including debt. The offer of 940 pence per share outbid rival CVC and has won the backing of Bodycote's board.
The price represents a 34.5% premium to Bodycote's closing price before takeover speculation emerged in May, underscoring how private equity firms are increasingly targeting what they see as undervalued UK-listed companies.
What's on the table
Under the terms, Bodycote shareholders will receive 932.8 pence in cash plus a 7.2 pence interim dividend, bringing the total to 940 pence per share. The deal values the company at roughly £1.85 billion including debt.
The bidding process has been competitive. Veritas and CVC had both previously indicated offers in the region of 914–915 pence per share in August, after Apollo abandoned a separate approach earlier in the summer. CVC has said it is now considering its next move, leaving the door open for a possible counterbid.
Bodycote is a global leader in thermal processing services—techniques that treat metals and other materials to improve their strength, durability, and resistance to wear. The company operates a network of facilities across more than 20 countries, serving industries including aerospace, automotive, energy, and medical devices.
Why private equity is circling UK stocks
The deal is the latest in a series of takeovers of UK-listed companies by private equity buyers, who have been drawn by what is often called the "UK discount." This refers to the tendency for UK stocks to trade at lower valuations compared with their US or European peers, making them attractive acquisition targets.
Several factors contribute to this discount, including uncertainty around Brexit, a weaker pound, and a perception that UK markets are less growth-oriented. For private equity firms, the gap between a company's market value and its intrinsic worth can create an opportunity to buy assets at a relatively low price, then improve operations and potentially sell later at a profit.
This trend has been particularly visible in the mid-cap segment of the London market, where companies like Bodycote—solid but not flashy—often trade at a discount to their global counterparts. The competition between Veritas and CVC for Bodycote shows how intense the bidding can become when multiple buyers see the same value.
What it means for investors
For current Bodycote shareholders, the offer represents a significant cash return. The 34.5% premium to the pre-speculation price means those who held the stock before the takeover talk began stand to gain a substantial windfall.
However, the deal is not yet done. CVC's statement that it is weighing its options means there is still a chance of a higher bid. Shareholders should watch for any further announcements from either party. If CVC returns with a higher offer, the board would need to consider whether it is in shareholders' best interests.
For investors in UK stocks more broadly, the Bodycote deal is a reminder that the "UK discount" can sometimes translate into real cash gains. But it also highlights a risk: companies that are undervalued may be taken over, removing them from the public market and leaving investors with cash instead of a long-term holding.
Private equity activity can be a double-edged sword. On one hand, it can boost share prices as buyers compete. On the other, it can reduce the number of investment opportunities available on the London Stock Exchange, which has seen a steady stream of companies leave the market in recent years.
Investors who own shares in other UK mid-caps may want to consider whether their holdings could be next. Sectors with strong cash flows, solid market positions, and relatively low valuations—like industrial services—are often prime candidates for private equity interest.
The Bodycote deal also comes at a time when foreign investors are returning to some emerging markets, but the UK's appeal to private equity remains strong. The outcome of this bidding war will be closely watched as a signal of how aggressive buyers are willing to be.
For now, Bodycote's board has recommended the Veritas offer, but the final price may not be set until CVC makes its decision. Shareholders should stay alert to developments, as the situation could change quickly.
